📰 Foresight Diagnostics News
Foresight Diagnostics News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Foresight Diagnostics. Real-time updates on events, politics, business and more.
January 5, 2024
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday.
January 5, 2024
By Colin Kellaher Shares of Allogene Therapeutics tumbled more than 15% on Friday after the clinical-stage biotechnology company unveiled a...
January 5, 2024
Allogene Therapeutics Inc (NASDAQ: ALLO) announced deprioritizing the currently enrolling third line Phase 2 ALPHA2 and EXPAND trials of cema-cel (ALLO-501A) and is now pursuing a potentially pivotal trial (ALPHA3) evaluating cema-cel as a consolidation therapy in large B-cell lymphoma (LBCL) patients
January 4, 2024
Partnership Will Utilize Foresight’s Ultra-Sensitive MRD Technology to Identify Patients for Enrollment in Allogene’s ALPHA3 Trial SAN FRANCISCO and BOULDER, Colo., Jan. 04, 2024 -- Allogene...
August 17, 2023
/PRNewswire/ -- Foresight Diagnostics, a leading provider of ultrasensitive cancer detection tests, today announced the appointment of John Truesdell as Chief...
August 8, 2023
FREMONT, Calif.--(BUSINESS WIRE)--Aug 8, 2023--
June 26, 2023
By Sabela Ojea Personalis Inc. said Monday it sued Foresight Diagnostics for allegedly infringing three patents, months after suing the same company over...
June 26, 2023
Infringed patents part of industry-leading intellectual property position in whole genome, tumor-informed minimal residual disease testing
June 26, 2023
FREMONT, Calif.--(BUSINESS WIRE)--Jun 26, 2023--